Their clinical relevance was supported by the altered expression of these genes in CLL patients expressing high levels of UGT2B17 in a cohort of 448 cases (GSE13159) dichotomized on the basis of median UGT2B17 expression (Figure 2E). Here, UGT2B17 is linked to B-cell chronic lymphocytic leukemia.